Skip to Content

Belatacept Dosage

Applies to the following strength(s): 250 mg

The information at is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Rejection Prophylaxis

Initial dose: 10 mg/kg, intravenously, once daily, on day 1 (day of transplant, prior to implantation) and day 5, and at the end of weeks 2, 4, 8, and 12.

Maintenance dose: 5 mg/kg, intravenously, at the end of week 16 and every 4 weeks (plus or minus 3 days) thereafter.

Belatacept should be administered in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids. In clinical trials the median corticosteroid doses were tapered to approximately 15 mg per day by the first 6 weeks and remained at approximately 10 mg per day for the first 6 months post-transplant. Corticosteroid utilization should be consistent with the clinical trial experience.

Renal Dose Adjustments

Data not available.

Liver Dose Adjustments

Data not available.

Dose Adjustments

No dosage adjustment is recommended based on gender, weight, ethnicity, or geriatric status.


The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for belatacept. It includes a Medication Guide and communication plan. For additional information:

Due to an increased risk of posttransplant lymphoproliferative disorder (PTLD), progressive multifocal leukoencephalopathy (PML), and serious CNS infections, administration of higher than the recommended doses or more frequent dosing of belatacept is not recommended.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).


Data not available.

Other Comments

Belatacept is to be used in combination with basiliximab induction, mycophenolate mofetil and corticosteroids.

The total infusion dose of belatacept should be based on the actual body weight of the patient at the time of transplantation and should not be modified during the course of therapy unless there is a change in body weight of greater than 10%.

The prescribed dose of belatacept must be evenly divisible by 12.5 mg in order for the dose to be prepared accurately using the reconstituted solution and the silicone free disposable syringe provided.

Belatacept must be prepared using only the silicone-free disposable syringe provided with each vial.

The manufacturer's product information should be consulted for complete reconstitution and dilution recommendations.